Citadel Advisors
ACET icon

Citadel Advisors’s Adicet Bio ACET Stock Holding History

Citadel Advisors’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74M Buy
432,738
+50,915
+13% +$401K ﹤0.01% 5242
2026
Q1 		$2.6M Buy
381,823
+274,009
+254% +$2.05M ﹤0.01% 5540
2025
Q4 		$908K Buy
107,814
+71,317
+195% +$788K ﹤0.01% 7607
2025
Q3 		$473K Buy
36,497
+7,722
+27% +$91K ﹤0.01% 9264
2025
Q2 		$281K Sell
28,775
-49,269
-63% -$520K ﹤0.01% 9960
2025
Q1 		$943K Buy
78,044
+76,779
+6,069% +$1.1M ﹤0.01% 7086
2024
Q4 		$19.5K Sell
1,265
-1,429
-53% -$27K ﹤0.01% 13199
2024
Q3 		$62.1K Sell
2,694
-29,372
-92% -$657K ﹤0.01% 11664
2024
Q2 		$621K Buy
32,066
+17,178
+115% +$460K ﹤0.01% 7603
2024
Q1 		$560K Buy
14,888
+6,561
+79% +$271K ﹤0.01% 8129
2023
Q4 		$252K Buy
8,327
+2,138
+35% +$46.6K ﹤0.01% 9507
2023
Q3 		$136K Buy
6,189
+4,594
+288% +$162K ﹤0.01% 10512
2023
Q2 		$62K Sell
1,595
-17,966
-92% -$1.59M ﹤0.01% 11543
2023
Q1 		$1.8M Sell
19,561
-4,317
-18% -$542K ﹤0.01% 5588
2022
Q4 		$3.42M Buy
23,878
+7,533
+46% +$1.88M ﹤0.01% 4535
2022
Q3 		$3.72M Buy
16,345
+9,811
+150% +$2.49M ﹤0.01% 4385
2022
Q2 		$1.53M Buy
6,534
+798
+14% +$175K ﹤0.01% 6099
2022
Q1 		$1.83M Buy
5,736
+3,383
+144% +$778K ﹤0.01% 6282
2021
Q4 		$658K Buy
+2,353
New +$404K ﹤0.01% 8988
2021
Q2 		– Sell
-1,776
Closed -$355K – 13573
2021
Q1 		$355K Buy
+1,776
New +$408K ﹤0.01% 10451
2020
Q2 		– Sell
-314
Closed -$36K – 9690
2020
Q1 		$36K Buy
+314
New +$46.6K ﹤0.01% 9144
2018
Q2 		– Sell
-102
Closed -$110K – 8748
2018
Q1 		$110K Buy
+102
New +$187K ﹤0.01% 7678

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Citadel Advisors's ACET Position: Q2 2026 in Review

Citadel Advisors increased its Adicet Bio (ACET) stake by 13% in Q2 2026, buying an estimated $401K and bringing the position to 432,738 shares worth $3.74M. The position accounts for ﹤0.01% of the portfolio, ranked #5242.

Citadel Advisors first reported a position in ACET in Q1 2018 and has held it in 22 quarters since. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Citadel Advisors held 432,738 shares of Adicet Bio worth $3.74M as of Q2 2026.
  • Citadel Advisors bought 50,915 Adicet Bio shares in Q2 2026, an estimated $401K.
  • Adicet Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5242 holding.
  • Citadel Advisors first reported a position in Adicet Bio in Q1 2018 and has held it in 22 quarters since.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.